Antimetastatic action of diltiazem on LS/BL tumor cells in liver tumor-colony assay.

Inhibition of experimental metastases of lymphosarcoma LS/BL cells by diltiazem, a calcium blocking agent, was tested. Diltiazem treatment (2 X 30 mg/kg p.o. for 12 days) resulted in a maximum of 72.8% inhibition of liver metastases. The authors suggest that diltiazem might become suitable candidate for antimetastatic treatment in humans.